Mineralys Therapeutics (MLYS) Corporate Update
Market Performance (as of 23 Oct 2026, 12:27 PM CET)
| Item | Value |
|---|---|
| Current price | USD 21.47 |
| 24‑hour change | –2.22 % |
| 24‑hour trading volume | USD 17.1 million |
| 24‑hour volume in shares | 88.6 million |
| Market capitalization | USD 1.9 billion |
| Simple moving average (200 days) | USD 27.45 |
| 52‑week high | USD 47.65 (12 Nov 2025) |
| 52‑week low | USD 20.12 (16 Oct 2026) |
| Month‑to‑date change | –28.23 % |
The stock closed down 2.22 % during the 24‑hour period ending at 12:27 PM Central Europe time on Friday 23 Oct 2026. The trading volume of USD 17.1 million represents a total of 88.6 million shares traded.
Recent Scientific Development
Mineralys Therapeutics reported Phase‑3 data for its investigational drug lorundrostat at the American Society of Nephrology Kidney Week conference. Key findings include:
- Significant reductions in systolic blood pressure in patients with hypertension, across chronic kidney disease stages 1‑3.
- A roughly 50 % reduction in urine albumin‑to‑creatinine ratio in participants with baseline albuminuria compared with placebo.
- Low incidence of hyperkalemia, especially in non‑kidney‑diseased patients.
Lorundrostat remains under review by the U.S. Food and Drug Administration for the treatment of hypertension, with a target decision date set for late December 2026. The program targets patients with concomitant kidney disease, addressing a noted unmet clinical need.
Related Stock Activity (24‑hour period)
| Company | Ticker | 24‑hour change | Current price | Market cap | P/E ratio |
|---|---|---|---|---|---|
| Addus Homecare | ADUS | +4.00 % | USD 122.67 | USD 2.2 billion | 20.67 |
| PC Connection | CNXN | +0.89 % | USD 88.51 | USD 2.2 billion | 23.22 |
| Encore Capital | ECPG | –3.65 % | USD 100.36 | USD 2.2 billion | 7.88 |
| Agios Pharmaceuticals | AGIO | +0.03 % | USD 37.19 | USD 2.2 billion | – |
| Harmony Biosciences | HRMY | –1.01 % | USD 36.03 | USD 2.2 billion | 12.4 |
Notable Corporate Actions
- PC Connection: Form 4 filings reported multiple large sales of common stock by the David Hall Trust 2003 and related entities, with a weighted average sale price ranging from the mid‑$80s to the low‑$90s. No governance changes were disclosed; filings complied with SEC Rule 10(b)(5‑1).
- Agios Pharmaceuticals: Two Rule 144 notices filed in late October 2026 reported the sale of 1,489 shares on 21 Oct and 500 shares on 22 Oct by officer Sarah Gheuens. Both transactions were executed through a brokerage service on the Nasdaq exchange and involved cash payments.
Company Profile
Mineralys Therapeutics, Inc. is a clinical‑stage biopharmaceutical company headquartered in Wayne, United States, operating within the Health Care sector. The company focuses on developing aldosterone synthase inhibitors (ASI) for the treatment of uncontrolled hypertension. It is listed on the Nasdaq stock exchange under the ticker MLYS. The initial public offering took place on 9 Feb 2023. Further information is available on the company’s website, www.mineralystx.com .
